A massive review of trials now points to a higher chance of death in adults treated with the common hospital antibiotic cefepime compared with other beta-lactams.
Story Snapshot
- A 2026 synthesis of 110 trials found a 94.4% chance cefepime raises mortality odds versus peers.
- Published, peer-reviewed trials showed a stronger signal in adults, with an odds ratio of 1.17.
- Earlier analyses saw the same hint, but the Food and Drug Administration review in 2010 downplayed it.
- The risk did not appear in children, and the likely drivers remain unclear.
The new analysis that put cefepime back under the microscope
JAMA Network Open published a systematic review and Bayesian meta-analysis in 2026 that pooled 110 randomized trials with 22,608 patients. The team reported a 94.4% probability that cefepime increased the odds of death compared with other beta-lactam antibiotics.
The pooled odds ratio was 1.10, and the 95% credible interval ranged from 0.98 to 1.24, which leaves some uncertainty in the full set. Yet the adult signal stood out and drove headlines.
A commonly used drug has been linked to a higher risk of death in a new study. https://t.co/CZapynlP56
— FOX 32 News (@fox32news) September 16, 2026
When the authors looked only at published, peer-reviewed trials, the signal grew stronger. Across 73 trials and 15,411 patients, cefepime showed an odds ratio of 1.17 with a 95% credible interval of 1.02 to 1.34.
That pushes the result into conventional “statistically significant” territory for that subset. Reports summarized a number needed to harm close to 111 in that published slice, which is not trivial if you run a busy hospital ward.
Why this matters at the bedside
Doctors often pick cefepime first for very sick adults because it covers many tough bacteria. If a broad-spectrum peer offers equal coverage with a lower chance of death, stewardship teams should weigh that.
The 2026 paper said the mortality signal did not hinge on one comparator drug, one diagnosis, or a small dose range. The effect spread across indications and seemed stronger at higher doses that many intensive care units use.
The same coverage noted that the apparent harm sat almost entirely in adults, with no increase seen in children. That aligns with the known risk of cefepime-related brain side effects in older or renally impaired adults.
The meta-analysis did not prove a mechanism, but the adult-only pattern fits common sense for cautious clinicians who already adjust doses in kidney disease.
The long fight over the cefepime mortality signal
This debate is not new. A 2007-era trial meta-analysis reported higher all-cause mortality with cefepime than with other beta-lactams. That warning pushed the Food and Drug Administration to review more data, including unpublished trials.
In 2010, a Clinical Infectious Diseases paper reported no statistically significant mortality increase in trial-level or patient-level analyses, which cooled the alarm for years.
The new 2026 Bayesian approach reframed the question. Instead of asking only if the interval excludes zero, it asked how likely harm is across the evidence.
The answer was “very likely,” even though the full 110-trial credible interval crossed neutrality. That nuance explains why some news focused on adults and the published-trial subset, where the estimate cleared the usual threshold.
How to act while the statisticians keep arguing
Hospitals do not need to wait for perfect proof to trim avoidable risk. Practical steps are clear: check kidney function early, avoid excessive dosing in older adults, and consider alternatives like piperacillin-tazobactam or meropenem when coverage is equal and patient risk is high. That is stewardship built on prudence, not panic.
A massive new review of medical data published in JAMA Network Open has brought renewed attention to cefepime, a widely utilized antibiotic for severe bacterial infections. Researchers analyzing over 100 historical clinical trials involving more than 22,500 patients identified a… pic.twitter.com/cZ3CKqHxAP
— Science & Nature (@ScienceIsNew) September 15, 2026
Critics point to the 2010 findings and say the signal drifts with trial selection. They are right that pooled results can swing when you mix published and unpublished data or group many infections together.
But the adult pattern now repeats across eras and methods. That repetition should move policy. Keep cefepime for cases where it is the best match, but stop making it the default when a safer peer can handle the job at the same speed.
What to watch next
Researchers should dig into adult subgroups with high cefepime exposure, renal impairment, and intensive care use to test dose-response and mechanism.
Trial-level data can separate monotherapy from combination therapy and compare cefepime head-to-head with piperacillin-tazobactam and meropenem.
Until then, stewardship committees can update order sets, require renal dose checks at 24 hours, and prompt providers to document a reason when choosing cefepime over an equal alternative.
Sources:
foxnews.com, pubmed.ncbi.nlm.nih.gov, medpagetoday.com
